Long-term hypotensive effect of atenolol 4% eyedrops
|
|
- Miranda Lorin Garrison
- 6 years ago
- Views:
Transcription
1 British Journal of Ophthalmology, 1978, 62, Long-term hypotensive effect of atenolol 4% eyedrops R. F. BRENKMAN From the Department of Ophthalmology, University Hospital, Leiden, The Netherlands SUMMARY The effect of long-term application of 4 atenolol eye drops has been studied in patients with either glaucoma or ocular hypertension. n some patients who show a good initial response the ocular hypotensive effect gradually wears off with long-term use. This pattern of response appears to be more frequent in patients with pretreatment intraocular pressures of 25 mmhg, or greater. n combination with atenolol miotics or adrenaline show an additive effect. Phillips et al. (1967) published the first report of the ocular hypotensive effect of a beta-adrenergic blocking agent (propranolol). Subsequently several other compounds in this pharmacological class were studied, and a similar effect was found, examples being practolol, oxprenolol, and atenolol (Vale and Phillips, 1973; Stilma, 1977; Elliot et al., 1975; Wettrell and Pandolfi, 1975). Although propranolol is effective after topical administration (Vale and Phillips, 1970), it is considered to be unsuitable for therapeutic use by this route because of local irritant and anaesthetic effects. Practolol was well tolerated on topical administration but has been withdrawn because of side effects reported after oral administration (Rahi et al., 1976). The pharmacological profiles of the beta-adrenergic blocking agents differ considerably, and the only common property among those showing an ocular hypotensive effect is a 51-blocking effect (Table 1). Atenolol is a cardioselective (r1) blocking agent and is devoid of membrane stabilising and intrinsic sympathicomimetic effects. t is of interest that MacDonald et al. (1976) reported that atenolol produced a greater reduction in intraocular pressure than propranolol (a non-selective compound) on oral administration. Table 1 The pharmacological properties ofpropranolol, practolol, and atenolol Propranolol (nderal) r+1+.2 blockade membrane stabilising effect Practolol (Eraldin) 3, blockade little intrinsic sympathicomimetic activity Atenolol (Tenormin), blockade Address for reprints: Dr R. F. Brenkman, Department of Ophthalmology, University Hospital, Leiden, The Netherlands 287 Table 2 Material The study group patients (10 male, 6 female) in whom glaucoma had not previously been detected Age years (mean 61 years) Gonioscopic classification: wide angle 11 intermediate angle 5 narrow angle 0 (No special types of glaucoma) Table 3 The 4 groups ofpatients classified according to their base-line pressure (Bip) Group : Blp (base-line pressure) mmhg; 8 patients (5 glaucoma suspect) Group : Blp mmhg; 4 patients Group : Bp mmhg; 2 patients Group V: Bp mmhg; 1 patient The promising results of our single-dose study with 4% atenolol eyedrops (Brenkman, 1977) prompted us to investigate the ocular hypotensive effect of topical atenolol during long-term therapeutic use, either as sole therapy or in combination with miotic agents or adrenaline. Patients and methods The study group consisted of previously untreated patients (Table 2). Five patients were classified as ocular hypertensives, the remainder as suffering from open- or intermediate-angle glaucoma. Base-line intraocular pressure levels were recorded on 3 or 4 occasions over a period of several weeks, and the average of these values was used to classify the patients into 4 subgroups (Table 3).
2 288 R. F. Brenikman On the first day of atenolol treatment intraocular pressure was recorded for up to 7 hours after a single instillation (into both eyes) of 4% atenolol. Subsequently the patients were treated with 4% atenolol administered 3 times daily, and the intraocular pressure was recorded, 1, 2, 4, 8, and weeks later. f control of intraocular pressure was considered to be unsatisfactory on follow-up, atenolol was discontinued and alternative therapy instituted. n the majority of these cases the following sequence was followed until satisfactory control of intraocular pressure was regained: (1) soptocarpine 2%; (2) soptocarpine 2% + atenolol 4%; (3) Glaucadrine; (4) Glaucadrine + atenolol 4%; (5) Surgery. The procedure is summarised in Fig. 1, and the criterion of control was an intraocular pressure of 21 mmhg or less. lo.p readings Blp (Base line pressure) ; Single dose curve 1 ; i Long term effect i # T No therapy hours - + weeks T3h)_ Fig. 0~ E E A singie dose of Atenolol 4% eyedrops 3dd gtt 11 ODS Atenolol 47. if r6fficient resporse: soptocarpine 27. eyedrops soptocarpne 2P. * Atenobol 4% Plan of our research Glaucodrine GCaucodrine. Atenobl 4% Fall in OP after a singlee dose a.a.. x...x 'x 24/. Fall in.op.with regard to Blp - 25% -1 TO hours Fig. 2 Fall in intraocular pressure (lop) after a single dose of atenolol 40% eyedrops (Blp = base-line pressure) E \ 26 4, t\ 24 4' Blp hours 1 group ( Bp mm Hg; 8 patients, ---group ( B p mmhg;4patients, - - -_ group ( Blp mm Hg;2patients) group V ( Blp mm Hg; 1 patient) Single dose response 2 3 i~~~~~~~~~ weeks Long term effect Fig. 3 Single dose response curve according to the 4 groups ofpatients Patient x= ODS...- Patient 1-11 prevvious research ) o,26 - E group ( Blp mmhg, 8 patients) group 11 (Bp mmhg;4 patients) group (Blp mmhg;2 patients) group V ( Blp mmhg; 1 patient ) x stop x=ods Y stop ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ ~~ -" _ Long term effects stop Blp after: weeks Fig. 4 Long-term hypotensive effect of atenolol 4 % eyedrops according to the 4 groups ofpatients 0 _x_ - X cont.
3 Fig. 5a Base-line pressure, ofpatient (group ) 30 - E - Bip W r C//~~---. -,~~ hours-o weeks - Patient (group ) 8 Therapy: Atenolot 4% 3dd soptocc 3 Single dose 38 curve '30 ;.- arpine 2% isoptocarpine2%.atenalol 47% 1~ w Glaucardrine 1 Glaucardrne Atenoala 4'! A Fig. 5b Base-line pressure, ofpatient 22 (group ) hours weeks No Pqtent 22 (group ) Fig. 5c Base-line pressure, ofpatient 20 (group ) Thercpy:Atenobt 4% 3 dd Sngle dose curve ] 30 E 26 h PC7 - Therapy: Atenolol 4% 3dd J soptocarpine 2% Single dose / soptocarbachol 3%/ curve / Gaucadrine Bip r Glaucadrne Atenoblt 4% : curve ;Day hours-_ weeks Pcitient 20 (group m ) hrs ,F 30- E 26 & or a weeks Patient (group V) Fig. 5d Base-line pressure, ofpatient (group V)
4 290 0 E Atenobol -4.3 sopbocarpine -5 Atenobl 2% -7 Glaucadrirne 7-6 Atenolol Gb.acadrine '/. % % -9 28% % Blp Fig. 6. Long-term hypotensive effect of atenolol 4% eyedrops alone, with regard to, and in combination with, isoptocarpine 2% and Glaucadrine Results SNGLE-DOSE PHASE The group mean intraocular pressure levels were calculated for the different time points, and the resulting day curve was compared with similar data from a previous single-dose study (Fig. 2). The mean intraocular pressure reduction over the 7-hour follow-up period was 24% in this study, as compared to 25% in the previous study. n Fig. 3 the single-dose day curves are subdivided according to the previously described pretreatment pressure classification, and the magnitude of the ocular hypotensive effect appears to be dependent on the base-line pressure, though the number of subjects in the higher-pressure groups is small. MULTPLE-DOSE PHASE n the multiple-dose phase intraocular pressure was recorded at midday (i.e., 3 hours after the morning dose of atenolol), and the mean levels for the 4 subgroups are shown in Fig. 4. t can be seen that the majority of patients in groups -V were withdrawn from treatment with atenolol after 2 to 4 weeks because of diminution of the initial response to the drug. n contrast the majority of patients in group showed a sustained response to the drug over the -week follow-up period (1 patient only in this group was transferred to isoptocarpine after 4 weeks' therapy with atenolol). The responses of representative patients from each subgroup are shown in Figs. 5a to d. After discontinuation of atenolol the progress of the treatment failures was monitored through the secondary treatment sequence. t is of interest that none of these patients showed a satisfactory response to isoptocarpine alone. At the time of preparation of this report 1 patient was controlled on combined therapy with isoptocarpine and atenolol, 2 on Glaucadrine (2% aceclidine + 1% adrenaline) and atenolol, and 1 after glaucoma surgery. Two other R. F. Brenkman patients had entered the sequence, but follow-up data were not yet available. From analysis of the invidual intraocular pressure curves an attempt was made to evaluate the relative efficacy of the different therapeutic regimens. This analysis is summarised in Fig. 6. t suggests that atenolol has an additive effect with miotic agents and possibly also with adrenaline. However, the number of patients involved is too small to permit a meaningful statistical evaluation. Discussion The discrepancy between the initial (single-dose) response to atenolol and the subsequent response on longer-term treatment, observed in a proportion of the patients in this study, requires further investigation because of the therapeutic implications. The results of this study indicated a relationship between high pretreatment intraocular pressure levels and subsequent loss of effect during atenolol treatment. Tachyphylaxis to beta-adrenergic agonists is well documented (Langham, 1975; Paterson and Paterson, 1971) but is not known to be related to the pretreatment pressure level. t is of interest that the patients who showed loss of effect to atenolol also appeared relatively resistant to established glaucoma therapy. t is not known, however, whether these patients showed a first-dose response to isoptocarpine or Glaucadrine. This aspect of primary or secondary treatment failure should be carefully defined wherever feasible. Conclusions A single administration of atenolol 4% eyedrops produces an unequivocal reduction in intraocular pressure, with a maximum effect occurring between 3 and 5 hours after instillation. n a proportion of patients the ocular hypotensive effect diminishes over the next few weeks. The presence of pretreatment intraocular pressure in excess of 25 mmhg appears to predispose to this occurrence. Atenolol produces an additional ocular hypotensive effect when co-administered with adrenaline and/or miotic therapy. Atenolol eyedrops were kindly supplied by C Pharmaceuticals Ltd. We are grateful to Dr W. J. van Zijll and Dr A. Rushton for information and discussion. References Brenkman, R. F. (1977). Ocular hypotensive effect of atenolol 4 % eyedrops in glaucoma. Documenta Ophthalmologica Proceedings Series, Vol 12, pp 85-94, Junk: The Hague.
5 Long-term hypotensive effect of atenolol 4% eyedrops Elliot, M. J., Cullen, P. M., and Phillips, C.. (1975). Ocular hypotensive effect of atenolol (Tenormin, C) (a new beta-adrenergic blocker). British Journal of Ophthalmology, 59, Langham, M. E. (1975). Adrenergic tachyfylaxis in animal and human eyes. Experimental Eye Research, 20, MacDonald, M. J., Cullen, M. D., and Phillips, C.. (1976). Atenolol versus propranolol: a comparison of ocular hypotensive effects of an oral dose. British Journal of Ophthalmology, 60, Paterson, G. D., and Paterson, G. (1971). A comparison of the ocular hypotensive actions of salbutamol and adrenaline in chronic simple glaucoma. Postgraduate Medical Journal, 47, March supplement, 122. Phillips, C.., Howitt, G., and Rowlands, D. J. (1967). Propranolol as ocular hypotensive agent. British Journal of Ophthalmology, 51, Rahi, A. H. S., Chapman, C. M., Garner, A., and Wright, P. (1976). Pathology of practolol-induced ocular toxicity. British Journal of Ophthalmology, 60, Stilma, J. S. (1977). Use of oxprenolol eye drops in glaucoma patients. Documenta Ophthalmologica Proceedings Series, Vol. 12, pp Junk: The Hague. Vale, J., and Phillips, C.. (1970). Effect of DL- and D- propranolol on ocular tension in rabbits and patients. Experimental Eye Research, 9, Vale, J., and Phillips, C.. (1973). Practolol (Eraldin) eye drops as an ocular hypotensive agent. British Journal of Ophthalmology, 57, Wettrell, K., and Pandolfi, M. (1975). Effect of oral administration of various beta-blocking agents on the intraocular pressure in healthy volunteers. Experimental Eye Research, 21,
Atenolol eye drops in glaucoma:
Atenolol eye drops in glaucoma: a double-masked, controlled study British Journal of Ophthalmology, 1977, 61, 349-353 CALBERT. PHLLPS,' SHELA M. GORE,2 MARGARET J. MACDONALD, AND PATRCA M. CULLEN' 'From
More informationevaluation of these two combined
British Journal of Ophthalmology, 1978, 62, 296-31 Atenolol versus adrenaline eye drops and an evaluation of these two combined CALBERT I. PHILLIPS, SHEILA M. GORE,* AND PATRICIA M. GUNN From the Department
More informationOcular hypotensive effect of atenolol (Tenormin, I.c.i.)
Brit. J. Ophthal. (I 975) 59, 296 Ocular hypotensive effect of atenolol (Tenormin, I.c.i.) A new beta-adrenergic blocker MARGARET J. ELLIOT, PATRICIA M. CULLEN, AND CALBERT I. PHILLIPS From the Department
More informationDose response of oral timolol combined with
British Journal of Ophthalmology, 1982, 66, 242-246 Dose response of oral timolol combined with adrenaline ARNE OHRSTROM From the University Eye Clinic of Malmo and the Hospital of Koping, Sweden SUMMARY
More informationEffects of selective beta!- and beta 2 -adrenoreceptor agonists and antagonists on intraocular pressure in the cat
Effects of selective beta!- and beta 2 -adrenoreceptor agonists and antagonists on intraocular pressure in the cat Brenda K. Colasanti and Robert R. Trotter Ocular tension of cats was measured after topical
More informationGLAUCOMA. An Overview
GLAUCOMA An Overview Compiled by Campbell M Gold (2004) CMG Archives http://campbellmgold.com --()-- IMPORTANT The health information contained herein is not meant as a substitute for advice from your
More informationThe combination of guanethidine 3% and adrenaline 0-5% in 1 eyedrop (GA) in glaucoma treatment
British Journal of Ophthalmology, 1979, 63, 56-62 The combination of guanethidine 3% and adrenaline 0-5% in 1 eyedrop (GA) in glaucoma treatment PH. F. J. HOYNG AND C. L. DAKE From the Department of Ophthalmology,
More informationRECENT ADVANCES AND FUTURE PROSPECTS IN THE MEDICAL TREATMENT OF OCULAR HYPERTENSION*
Brit. J. Ophthal. (1954) 38, 742. RECENT ADVANCES AND FUTURE PROSPECTS IN THE MEDICAL TREATMENT OF OCULAR HYPERTENSION* BY R. WEEKERS, E. PRIJOT, AND J. GUSTIN From the Ophthalmological Clinic of the University
More informationDilating dangerous pupils
Dilating dangerous pupils R. MAPSTONE From St. Paul's Eye Hospital, Liverpool British Journal of Ophthalmology, 1977, 61, 517524 SUMMARY Altogether 85 eyes from patients at risk to the development of closedangle
More informationDrug therapy of glaucoma
288 GILLIAN D. PATERSON AND GAVIN PATERSON From the Glaucoma Unit, Moorfields Eye Hospital, High Holborn Branch, London, and the Department of Pharmacology, King's College, University of London Of the
More informationMetoprolol -a new cardioselective 3-adrenoceptor blocking agent for treatment of tachyarrhythmias
British Heart journal, 1977, 39, 834-838 Metoprolol -a new cardioselective 3-adrenoceptor blocking agent for treatment of tachyarrhythmias H. S. WASIR, R. K. MAHAPATRA, M. L. BHATIA, SUJOY B. ROY, AND
More informationFamily studies in glaucoma
Brit. j. Ophthal. (I 974) 58, 529 Family studies in glaucoma E. S. PERKINS Institute of Ophthalmology, University of London There is now strong evidence for a genetic basis to glaucoma. Numerous family
More informationPRESCRIBING INFORMATION MYDFRIN * Phenylephrine Hydrochloride Ophthalmic Solution. Vasoconstrictor and Mydriatic for Use in Ophthalmology
PRESCRIBING INFORMATION MYDFRIN * Phenylephrine Hydrochloride Ophthalmic Solution Vasoconstrictor and Mydriatic for Use in Ophthalmology Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd., Dorval,
More informationGlaucoma Disease Progression Role of Intra Ocular Pressure. Is Good Enough, Low Enough?
Glaucoma Disease Progression Role of Intra Ocular Pressure Is Good Enough, Low Enough? Glaucoma Diseases Progression Key Considerations Good number of patients may be diagnosed only after some damage the
More informationYOUR VYZULTA TREATMENT GUIDE. Please see Important Safety Information on pages 1, 9, 10, 17 and 18. Please see accompanying Prescribing Information.
YOUR VYZULTA TREATMENT GUIDE Please see Important Safety Information on pages 1, 9, 10, 17 and 18. Please see accompanying Prescribing Information. INDICATION VYZULTA TM (latanoprostene bunod ophthalmic
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 May 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 May 2008 COSOPT 20 mg/5 mg/ml, eye drops, solution in single dose container Box of 60 0.2 ml single dose containers
More informationThe Systemic Effect Of Topical Timolol On Some Cardiovascular Parameters In Owerri Municipality
ISPUB.COM The Internet Journal of Third World Medicine Volume 5 Number 1 The Systemic Effect Of Topical Timolol On Some Cardiovascular Parameters In Owerri Municipality G Oze, M Emegwamuo, P Eleanya, H
More informationBETAGAN Allergan Levobunolol HCl Glaucoma Therapy
BETAGAN Allergan Levobunolol HCl Glaucoma Therapy Action And Clinical Pharmacology: Levobunolol is a noncardioselective beta- adrenoceptor antagonist, equipotent at both beta1 and beta2 receptors. Levobunolol
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology The term ocular hypertension usually refers to any situation in which the pressure inside the eye, called intraocular pressure,
More informationThe biphasic intraocular pressure response of rabbits to epinephrine
The biphasic intraocular pressure response of rabbits to epinephrine Maurice E. Langham and Gunter K. Krieglstein A study has been made of the pupillary and intraocular pressure responses of conscious
More informationAbnormal intraocular pressure control
British Journal of Ophthalmology, 1980, 64, 845-851 Abnormal intraocular pressure control in systemic hypertension and diabetic mellitus BILLIE I. WILLIAMS,' W. S. PEART,1 AND E. LETLEY2 From the 'Medical
More informationEffect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial
European Journal of Ophthalmology / Vol. 13 no. 7, 2003 / pp. 611-615 Effect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial S.A. GANDOLFI, L. CIMINO, P.
More informationA. Incorrect! Acetazolamide is a carbonic anhydrase inhibitor given orally or by intravenous injection.
Pharmacology - Problem Drill 20: Drugs that Treat Glaucoma Question No. 1 of 10 1. is a topical carbonic anhydrase inhibitor. Question #01 (A) Acetazolamide (B) Clonidine (C) Dorzolamide (D) Apraclonidine
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationAdrenergic hypersensitivity after beta-blocker
BHJ 460/80 Adrenergic hypersensitivity after beta-blocker withdrawal P J ROSS, M J LEWS, D J SHERDAN, A H HENDERSON Br Heart7 1981; 45: 637-42 From the Departments of ardiology and Pharmacology, Welsh
More informationEffects of cigarette smoking on intraocular
British Journal of Ophthalmology, 1978, 62, 682-687 Effects of cigarette smoking on intraocular pressure and vision ROY J. SHEPHARD, ELLENOR PONSFORD, P. K. BASU, AND ROBERT LABARRE From the Department
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More information8 USE IN SPECIFIC POPULATIONS Patients with Open-Angle Glaucoma or Ocular Hypertension
3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Isopto Carpine safely and effectively. See full prescribing information for Isopto Carpine. Isopto
More informationSpontaneous Intraocular Pressure Reduction in Normal-Tension Glaucoma and Associated Clinical Factors
CLINICAL INVESTIGATIONS Spontaneous Intraocular Pressure Reduction in Normal-Tension Glaucoma and Associated Clinical Factors Akihiro Oguri, Tetsuya Yamamoto and Yoshiaki Kitazawa Department of Ophthalmology,
More informationA genetic basis has been postulated for
Intraocular pressure response to topical corticosteroids Bernard Becker The intraocular pressure response to topical betamethasone appears to be genetically determined. A study of patients with primary
More informationeffects of intravenous labetalol
Pharmacological basis for antihypertensive effects of intravenous labetalol D. A. RICHARDS,' B. N. C. PRICHARD, A. J. BOAKES, J. TUCKMAN, AND E. J. KNIGHT2 From the Department of Clinical Pharmacology,
More informationBeta Blockers for ENT Surgery
Beta Blockers for ENT Surgery Dr. Giuliano Michelagnoli U.O. Anestesia e Rianimazione Nuovo Ospedale di Prato Perioperative Beta-Blockade 1. Reduction of perioperative cardiovascular risk 2. Multimodal
More informationKEY MESSAGES. Details of the evidence supporting these recommendations can be found in the above CPG, available on the following websites:
QUICK REFERENCE FOR HEALTHCARE PROVIDERS KEY MESSAGES 1. Glaucoma is a chronic eye disease that damages the optic nerve, & can result in serious vision loss and irreversible blindness. 2. Glaucoma diagnosis
More informationCOMPARATIVE ANAESTHETIC PROPERTIES OF VARIOUS LOCAL ANAESTHETIC AGENTS IN EXTRADURAL BLOCK FOR LABOUR
Br.J. Anaesth. (1977), 49, 75 COMPARATIVE ANAESTHETIC PROPERTIES OF VARIOUS LOCAL ANAESTHETIC AGENTS IN EXTRADURAL BLOCK FOR LABOUR D. G. LITTLEWOOD, D. B. SCOTT, J. WILSON AND B. G. COVINO SUMMARY Various
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension 1.1 Short title Glaucoma 2 Background
More informationINDICATIONS ACULAR 0,5 % is indicated for the relief of inflammation following ocular surgery.
Page 1 of 5 SCHEDULING STATUS Schedule 3 PROPRIETARY NAME (AND DOSAGE FORM) ACULAR 0,5 % COMPOSITION ACULAR 0,5 % contains: Preservatives: Benzalkonium chloride 0,01 % m/v Disodium edetate 0,1 % m/v PHARMACOLOGICAL
More information53 year old woman attends your practice for routine exam. She has no past medical history or family history of note.
Case 1 Normal Tension Glaucoma 53 year old woman attends your practice for routine exam. She has no past medical history or family history of note. Table 1. Right Eye Left Eye Visual acuity 6/6 6/6 Ishihara
More informationTREATMENT TRACKER Indication LUMIGAN (bimatoprost ophthalmic solution) 0.01% is used for the reduction of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or
More informationelectrocardiogram at rest and on exercise
British Heart Journal, I971, 33, 473-480. Assessment of propranolol in angina pectoris Clinical dose response curve and effect on electrocardiogram at rest and on exercise B. N. C. Prichard' and P. M.
More informationGlaucoma Intraocular Pressure What Will I Notice?
Glaucoma Glaucoma is the name given to a group of eye conditions in which the optic nerve at the back of the eye is slowly damaged. The diagnosis of glaucoma is made when your optometrist or ophthalmologist
More informationPreservative-Free Tafluprost % in the Treatment of Patients with Glaucoma and Ocular Hypertension
Adv Ther (211) 28(7):575-585. DOI 1.17/s12325-11-38-9 ORIGINAL RESEARCH Preservative-Free Tafluprost.15% in the Treatment of Patients with Glaucoma and Ocular Hypertension Carl Erb Ines Lanzl Seid-Fatima
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
Guidelines for the medical treatment of chronic open angle glaucoma and ocular hypertension Summary: DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Diagnosis and management of ocular hypertension (OHT)
More informationBeta blockers in primary hypertension. Dr. Md. Billal Alam Associate Professor of Medicine DMC
Beta blockers in primary hypertension Dr. Md. Billal Alam Associate Professor of Medicine DMC Development of antihypertensive drugs Beta blockers 1958 - The first beta-blocker, dichloroisoproterenol, was
More informationThe Uniocular Drug Trial and Second-Eye Response to Glaucoma Medications
The Uniocular Drug Trial and Second-Eye Response to Glaucoma Medications Tony Realini, MD, 1 Robert D. Fechtner, MD, 2 Sean-Paul Atreides, MD, 3 Stephen Gollance, MD 2 Purpose: To determine if the intraocular
More informationcatecholamines (CA) such as noradrenaline
Localization of beta receptors in the anterior segment of the rat eye by a fluorescent analogue of propranolol M. Lahav,* E. Melamed,** Z. Dafna,* and D. Atlas*** A fluorescent analogue of propranolol,
More informationInstil one or two drops in the conjunctival sac(s) every three to four hours as needed.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NAPHCON FORTE Eye Drops 0.1% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Naphcon Forte contains naphazoline hydrochloride 1.0 mg in 1 ml (0.1%). Excipient with known
More informationLESSON ASSIGNMENT Given the trade and/or generic name of an adrenergic blocking agent, classify that agent as either an alpha or beta blocker.
LESSON ASSIGNMENT LESSON 8 Adrenergic Blocking Agents. TEXT ASSIGNMENT Paragraphs 8-1 through 8-5. LESSON OBJECTIVES 8-1. Given a group of statements, select the statement that best describes one of the
More informationIOP measurements: 8.00 am (trough drug levels) and am (peak drug levels)(2 hours post dose)
This overview of 2% eye drops was presented by Dr. Ravin N. Das, at Hotel Satya Ashoka, on 19-6-2004 in place of Dr. H. S. Ray due to unforseen circumstances. This dinner meeting was sponsored by Cipla
More informationOcular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study
Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study James H. Peace, M.D. 1, Casey K. Kopczynski, Ph.D. 2, and Theresa Heah, M.D. 2 1 Inglewood, CA 2
More informationInadequate diagnostic value of the
Brit. j. Ophthal. (1974) 58, 55 Inadequate diagnostic value of the water-drinking test J. A. ROTH Department of Experimental Ophthalmology, Institute of Ophthalmology, University of London There is a large
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More informationNEW ZEALAND DATA SHEET
TRUSOPT 2% Ophthalmic Solution dorzolamide hydrochloride 1 Trusopt 2% Opthalmic Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1mL of TRUSOPT 2% contains 20 mg dorzolamide (22.3 mg of dorzolamide
More informationVI.2.2 Summary of treatment benefits
EU-Risk Management Plan for Bimatoprost V01 aetiology), both OAG and ACG can be secondary conditions. Secondary glaucoma refers to any case in which another disorder (e.g. injury, inflammation, vascular
More informationProvocative tests in closed-angle glaucoma
Brit. 7. Ophthal. (I976) 6o, I 5 Provocative tests in closed-angle glaucoma R. MAPSTONE From St Paul's Eye Hospital, Liverpool The absence of a provocative test with proved predictive value, in s at risk
More informationA double-blind comparison of bisoprolol and atenolol in patients with essential hypertension
QJ Med 995; 88:55-5 A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension N.M. WHEELDON, T.M. MacDONALD, N. PRASAD, D. MACLEAN, L. PEEBLES and D.G. McDEVITT From
More informationAcute closed-angle glaucoma: an investigation into the effect of delay in treatment
British Journal of Ophthalmology, 1979, 63, 817-821 Acute closed-angle glaucoma: an investigation into the effect of delay in treatment JEFFREY S. HLLMAN From St. James's University Hospital, Leeds SUMMARY
More informationRestoring Sensitivity to Timolol After Long-Term Drift in Primary Open-Angle Glaucoma
Investigative Ophthalmology & Visual Science, Vol., No. 2, February 90 Copyright Association for esearch in Vision and Ophthalmology estoring Sensitivity to Timolol After ong-term Drift in Primary Open-Angle
More informationJMSCR Volume 03 Issue 04 Page April 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Blood Pressure and Cardiac Responses to Isotonic Exercise and Its Modification by Beta Adrenoreceptor Blockade in Human Subjects Authors
More informationPHARMACOLOGICAL PROBLEMS
PHARMACOLOGICAL PROBLEMS 1. A 69 year old woman suffering from CHF has been treated with.25 mg Digoxin tablet daily for last 3 months. But the heart failure is not controlled adequately. What will be the
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationEFFECTS OF PREDNISOLONE EYE DROPS*t
Brit. J. Ophthal. (1967) 51, 398 EFFECTS OF PREDNISOLONE EYE DROPS*t A TRIAL OF THE EFFECTS OF PREDNISOLONE PHOSPHATE EYE DROPS ON THE INTRA-OCULAR PRESSURE OF NORMAL VOLUNTEERS BY T. G. RAMSELL, W. TRILLWOOD,
More informationPreliminary report on effect of retinal panphotocoagulation on rubeosis iridis and
British Journal of Ophthalmology, 1977, 61, 278-284 Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma LEILA LAATIKAINEN From Moorfields Eye Hospital,
More informationPresent relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS.
Course title: The Glaucoma Compass Course length: 1 hour +/- 31 slides Corse Description: Even with the technology and available information, glaucoma decision making can still be confusing. How should
More informationApplication for the deletion of bevacizumab (Avastin ) on the WHO Model List of Essential Medicines
21 st Expert Committee on the Selection and Use of Essential Medicines Application for the deletion of bevacizumab (Avastin ) on the WHO Model List of Essential Medicines Submitted by F. Hoffmann-La Roche
More informationPractolol and bendrofluazide in treatment of hypertension
British Heart Journal, I974, 36, 867-87I. Practolol and bendrofluazide in treatment of hypertension D. B. Galloway, A. G. Beattie, and J. C. Petrie From Department of Therapeutics and Clinical Pharmacology,
More informationIntraocular pressure, systemic blood pressure, and
g i MEDICAL MONTEFIORE MLDK'\?TA L.,PA British Journal of Ophthalmology, 1987, 71, 245-249 Intraocular pressure, systemic blood pressure, and age: a correlational study MICHAEL SCHULZER' AND STEPHEN M
More informationDr. Vishaal Bhat. anti-adrenergic drugs
Dr. Vishaal Bhat anti-adrenergic drugs Divisions of human nervous system Human Nervous system Central Nervous System Peripheral Nervous System Autonomic Nervous System Nervous system Includes neurons and
More informationOriginal Article. Abstract. Introduction. C Olali, G Malietzis, S Ahmed, E Samaila 1, M Gupta
Original Article Real-life experience study of the safety and efficacy of travoprost 0.004% / timoptol 0.50% fixed combination ophthalmic solution in intraocular pressure control C Olali, G Malietzis,
More informationEffect of walking on the ocular tension
Brit. j. Ophthal. (97) 56, 16 Effect of walking on the ocular tension in open-angle glaucoma D. A. LEGHTON Manchester Royal Eye Hospital n a previous paper (Leighton and Phillips, 197) it was shown that
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More information4/06/2013. Medication Observation POAG. Proportion. Native American 0.1% 0.4%
Clinical Research in Glaucoma: Putting Science into Practice J. James Thimons, O.D., FAAO Chairman, National Glaucoma Society www.nationalglaucomasociety.org Ocular Hypertension Treatment Study (OHTS)
More informationHYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014
HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted
More informationsympathetic nerve impulses endogenous catecholamines beta adrenergic drugs
Beta adrenergic blockers } These drugs will bind and prevent beta-receptors from responding to: sympathetic nerve impulses endogenous catecholamines beta adrenergic drugs the use of beta antagonists is
More informationIs this glaucoma? Leo Semes, OD Michael Chaglasian, OD Danica Marrelli, OD. Optometry s Meeting 2015 Seattle, WA
Is this glaucoma? Leo Semes, OD Michael Chaglasian, OD Danica Marrelli, OD Optometry s Meeting 2015 Seattle, WA Case 1. 54 WM Engineer is referred to UAB Eye Care as a glaucoma suspect. Mild myopic refractive
More informationAdrenergic Receptor Antagonists
Adrenergic Receptor Antagonists α-adrenergic Receptor Antagonists Unlike the β-adrenergic receptor antagonists, which bear clear structural similarities to the adrenergic agonists E, epinephrine, and isoproterenol,
More informationFluctuation of Intraocular Pressure and Glaucoma Progression in the Early Manifest Glaucoma Trial
Fluctuation of Intraocular Pressure and Glaucoma Progression in the Early Manifest Glaucoma Trial Boel Bengtsson, PhD, 1 M. Cristina Leske, MD, MPH, 2 Leslie Hyman, PhD, 2 Anders Heijl, MD, PhD, 1 Early
More information48 HYPERTENSION VOL 7, No 1, JANUARY-FEBRUARY 1985
48 HYPERTENSON VOL 7, No 1, JANUARY-FEBRUARY 1985 stricter responses were evoked by electrical stimulation of the renal nerves via platinum electrodes with the use of parameters that activate adrenergic
More informationOcular hypertension-a long-term follow-up of treated and untreated patients
British Jouirnal of Ophthalmology, 1977, 61, 668-674 Ocular hypertension-a long-term follow-up of treated and untreated patients ROBERT DVID, DESIREE G LIVINGSTON, ND MURICE H LUNTZ From the Department
More informationProvocative testing for primary open-angle glaucoma in "senior citizens" Norman Ballin* and Bernard Becker
Provocative testing for primary open-angle glaucoma in "senior citizens" Norman Ballin* and Bernard Becker A group of "senior citizens" was studied with respect to applanation pressures, water-provocative
More informationConsiderations in the Cataract Patient with Glaucoma. Robert Noecker, MD, MBA Ophthalmic Consultants of Connecticut Fairfield, CT
Considerations in the Cataract Patient with Glaucoma Robert Noecker, MD, MBA Ophthalmic Consultants of Connecticut Fairfield, CT Financial Disclosure Dr. Noecker has been a paid consultant to Allergan,
More informationPRODUCT MONOGRAPH. ratio-levobunolol. Levobunolol Hydrochloride Ophthalmic Solution 0.25% and 0.5% Glaucoma Therapy
PRODUCT MONOGRAPH ratio-levobunolol Levobunolol Hydrochloride Ophthalmic Solution 0.25% and 0.5% Glaucoma Therapy Noncardioselective beta-adrenoceptor blocking agent Teva Canada Limited DATE OF PREPARATION:
More informationa role for beta-blockers in the secondary prevention of myocardial heart disease.
BRITISH MEDICAL JOURNAL VOLUME 286 26 MARCH 1983 NTew Drugs Beta-blockers and sympathomimetics JOHN FEELY, PHILIP J DE VANE, DEREK MACLEAN The availability of some 10 different beta-adrenoceptor blockers
More informationPRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. BETOPTIC (betaxolol hydrochloride) Eye Drops 0.5%
PRODUCT INFORMATION BETOPTIC (betaxolol hydrochloride) Eye Drops 0.5% BETOPTIC S (betaxolol hydrochloride) Eye Drops 0.25% NAME OF THE MEDICINE BETOPTIC Eye Drops 0.5% and BETOPTIC S Eye Drops 0.25% contain
More informationChemistry 106: Drugs in Society Lecture 20: How do Drugs Elicit an Effect? Interactions between Drugs and Macromolecular Targets II 5/11/18
Chemistry 106: Drugs in Society Lecture 20: How do Drugs Elicit an Effect? Interactions between Drugs and Macromolecular Targets II 5/11/18 By the end of this session, you should be able to 1. Define enzyme
More informationGlaucoma. Glaucoma. Optic Disc Cupping
Glaucoma What is Glaucoma? Bruce James A group of diseases in which damage to the optic nerve occurs as a result of intraocualar pressure being above the physiological norm for that eye Stoke Mandeville
More informationPooling Data from Similar Randomized Clinical Trials Comparing Latanoprost with Timolol; Medical Results and Statistical Aspects
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1235 Pooling Data from Similar Randomized Clinical Trials Comparing Latanoprost with Timolol; Medical Results and Statistical
More informationEfficacy and Tolerability of Latanoprost 0.005% in Treatment of Primary Open Angle Glaucoma (POAG)
Original Article Efficacy and Tolerability of Latanoprost.5% in Treatment of Primary Open Angle Glaucoma (POAG) Muhammad Imran Janjua, Saira Bano, Ali Raza Pak J Ophthalmol 217, Vol. 33, No. 3.....................................................................................................
More informationCarvedilol or Propranolol in the Management of Portal Hypertension?
Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA
More informationPRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.
PRESCRIBING INFORMATION WITH CONSUMER INFORMATION Pr MYDRIACYL tropicamide ophthalmic solution, USP 0.5% and 1% w/v Anticholinergic Alcon Canada Inc. 2665 Meadowpine Blvd. Mississauga, ON L5N 8C7 www.alcon.ca
More informationCORNEO-SCLERAL TONOGRAPHY* t BY T. H. HODGSON AND R. K. MACDONALD From the Department of Ophthalmology, University of Toronto, Canada
Brit. J. Ophthal. (1957) 41, 301. CORNEO-SCLERAL TONOGRAPHY* t BY T. H. HODGSON AND R. K. MACDONALD From the Department of Ophthalmology, University of Toronto, Canada THAT pressure exerted on the eyeball
More informationAND PROPRANOLOL IN HYPERTHYROIDISM
Br. J. clin. Pharmac. (78),,-7 COMPARATIVE TRIAL OF ATENOLOL AND PROPRANOLOL IN HYPERTHYROIDISM D.G. McDEVITT Department of Therapeutics and Pharmacology, The Queen's University, Belfast, Northern Ireland
More informationCalculation of Trough-to-Peak Ratio in the Research Unit Setting
A]H 1996; 9:71S-75S Calculation of Trough-to-Peak Ratio in the Research Unit Setting Advantages and Disadvantages Henry L. Elliott and Peter A. Meredith The trough-to-peak ratio for the response to an
More informationNAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Naphcon-A contains naphazoline hydrochloride
More informationPharmacology of the Sympathetic Nervous System II
Pharmacology of the Sympathetic Nervous System II Edward JN Ishac, Ph.D. Professor Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
NEW ZEALAND DATA SHEET 1. PRODUCT NAME ISOPTO CARPINE pilocarpine hydrochloride eye drops 1% ISOPTO CARPINE pilocarpine hydrochloride eye drops 2% ISOPTO CARPINE pilocarpine hydrochloride eye drops 4%
More informationP. TURNER M.D., F.R.C.P. (Briant, Reid and Dollery, 1973), is impaired by. treatment with tricyclic antidepressant drugs. Since
Postgraduate Medical Journal (December 1974) 5, 729-733. Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness C. DE B. WHITE M.R.C.P. Summary In the treatment
More informationReason for Unscheduled Visit
Page 1 of 7 OHUN16.01 MULE: UNREASONS Reason for Unscheduled Visit * On any given page, any section started should be completed. Check all that apply: 1. Confirmation of IOP... Complete Snellen, IOP, Ocular
More information